Boston Scientific Closes Acquisition of Silk Road Medical, Inc.

Rhea-AI Summary

Boston Scientific (NYSE: BSX) has completed its acquisition of Silk Road Medical, Inc. (Nasdaq: SILK) for $27.50 per share, representing an enterprise value of approximately $1.18 billion. This acquisition strengthens Boston Scientific's vascular technology solutions by integrating the innovative transcarotid artery revascularization (TCAR) platform for stroke prevention and carotid artery disease treatment.

The deal is expected to have a minimal impact on Boston Scientific's adjusted earnings per share in 2024 and 2025, becoming accretive thereafter. The impact on GAAP earnings may be less favorable due to amortization expenses and acquisition-related charges. This strategic move aims to expand the availability of TCAR to more physicians and patients through Boston Scientific's extensive commercial network.

Positive

• Acquisition of Silk Road Medical strengthens Boston Scientific's vascular technology portfolio
• Integration of TCAR platform expands treatment options for carotid artery disease
• Potential for improved patient outcomes and reduced stroke risk
• Expected to be accretive to adjusted earnings per share after 2025
• Leverages Boston Scientific's commercial reach to expand TCAR availability

Negative

• Significant acquisition cost of $1.18 billion
• Immaterial impact on adjusted earnings per share in 2024 and 2025
• Potential dilution to GAAP earnings due to amortization and acquisition-related charges

Financial Analyst

The acquisition of Silk Road Medical by Boston Scientific for $1.18 billion is a strategic move to enhance its vascular technology portfolio. The deal, priced at $27.50 per share, demonstrates Boston Scientific's commitment to expanding its presence in the stroke prevention and carotid artery disease treatment market. Key financial implications:

• Expected to be earnings neutral in the short term (2024-2025)
• Potentially accretive to adjusted EPS beyond 2025
• GAAP earnings may be less favorable due to amortization and acquisition-related charges

This acquisition aligns with industry trends of larger medtech companies acquiring innovative smaller firms to boost their product offerings and market share. The neutral short-term financial impact suggests a focus on long-term growth and market positioning rather than immediate earnings boost.

Medical Research Analyst

The acquisition of Silk Road Medical brings the innovative TCAR (transcarotid artery revascularization) platform into Boston Scientific's portfolio, representing a significant advancement in stroke prevention and carotid artery disease treatment. Key medical implications:

• TCAR offers a minimally invasive alternative to traditional carotid endarterectomy
• Potential for reduced stroke risk during and after the procedure
• Wider access to TCAR through Boston Scientific's extensive distribution network

This move could accelerate the adoption of TCAR, potentially improving patient outcomes in carotid artery disease treatment. The integration of this technology into a major medtech company's portfolio may also spur further research and development in this field, potentially leading to refinements and improvements in the TCAR technique.

Market Research Analyst

Boston Scientific's acquisition of Silk Road Medical is a strategic play in the growing market for minimally invasive vascular treatments. Market implications:

• Strengthens Boston Scientific's position in the vascular intervention segment
• Potential for increased market share in the carotid artery disease treatment space
• Aligns with the trend towards less invasive surgical procedures

This acquisition could reshape the competitive landscape in the vascular device market, potentially pressuring other players to innovate or consolidate. The $1.18 billion valuation suggests high confidence in the TCAR technology's market potential. As minimally invasive procedures continue to gain favor among patients and healthcare providers, this move positions Boston Scientific to capitalize on this growing trend in vascular care.

MARLBOROUGH, Mass., Sept. 17, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced the close of its acquisition of Silk Road Medical, Inc. (Nasdaq: SILK), a medical device company that pioneered a new approach for stroke prevention and the treatment of carotid artery disease through a minimally invasive procedure called transcarotid artery revascularization (TCAR).

"Completing this acquisition enables Boston Scientific to strengthen our vascular technology solutions by bringing the innovative TCAR platform to a greater number of physicians and their patients through our significant commercial reach," said Cat Jennings, president, Vascular, Peripheral Interventions, Boston Scientific. "The integration of the TCAR platform into our portfolio means we can offer a treatment option for patients suffering from carotid artery disease that can reduce the risk of stroke and lead to improved patient outcomes."

The acquisition includes a purchase price of $27.50 per share, reflecting an enterprise value of approximately $1.18 billion.ⁱ The impact to Boston Scientific adjusted earnings per share is expected to be immaterial in 2024 and 2025, and accretive thereafter. The impact to GAAP earnings per share is expected to be less accretive, or dilutive, as the case may be, due to amortization expense and acquisition-related net charges.

About Boston Scientific
Boston Scientific transforms lives through innovative medical technologies that improve the health of patients around the world. As a global medical technology leader for more than 45 years, we advance science for life by providing a broad range of high-performance solutions that address unmet patient needs and reduce the cost of health care. Our portfolio of devices and therapies helps physicians diagnose and treat complex cardiovascular, respiratory, digestive, oncological, neurological and urological diseases and conditions. Learn more at www.bostonscientific.com and connect on LinkedIn and X, formerly Twitter.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding financial and business impact of the transaction and anticipated benefits of the transaction, business plans and strategy, product launches and product performance and impact. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the forward-looking statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

Risks and uncertainties that may cause such differences include, among other things: economic, political, competitive, reimbursement and regulatory conditions; geopolitical events; manufacturing, distribution and supply chain disruptions and cost increases; disruptions caused by cybersecurity events; disruptions caused by public health emergencies or extreme weather or other climate change-related events; labor shortages and increases in labor costs; variations in outcomes of ongoing and future clinical trials and market studies; new product introductions and the market acceptance of those products; market competition for our products; expected pricing environment; expected procedural volumes; demographic trends; the closing and integration of acquisitions, including our ability to achieve the anticipated benefits of the transaction and successfully integrate Silk Road Medical's operations; business disruptions (including disruptions in relationships with employees, customers and suppliers) following the announcement and/or closing of the transaction; intellectual property rights; litigation; financial market conditions; the execution and effect of our business strategy, including our cost-savings and growth initiatives; and future business decisions made by us and our competitors. New risks and uncertainties may arise from time to time and are difficult to predict. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A – Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission ("SEC"), which we may update in Part II, Item 1A – Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file hereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements, except as required by law. This cautionary statement is applicable to all forward-looking statements contained in this press release.

CONTACTS:
Blake Rouhani
Media Relations
(763) 494-2268
blake.rouhani@bsci.com

Jon Monson
Investor Relations
(508) 683-5450
BSXInvestorRelations@bsci.com

ⁱ Enterprise value of approximately $1.18 billion based on approximately 46.5 million fully diluted shares (or approximately $1.28 billion for 100% of the equity) and an estimated $104 million net cash position

View original content to download multimedia:https://www.prnewswire.com/news-releases/boston-scientific-closes-acquisition-of-silk-road-medical-inc-302250314.html

SOURCE Boston Scientific Corporation

FAQ

What is the acquisition price for Silk Road Medical by Boston Scientific (BSX)?

Boston Scientific (BSX) acquired Silk Road Medical for $27.50 per share, reflecting an enterprise value of approximately $1.18 billion.

How will the Silk Road Medical acquisition affect Boston Scientific's (BSX) earnings?

The acquisition is expected to have an immaterial impact on Boston Scientific's (BSX) adjusted earnings per share in 2024 and 2025, becoming accretive thereafter. The impact on GAAP earnings may be less favorable due to amortization and acquisition-related charges.

What technology does Boston Scientific (BSX) gain from acquiring Silk Road Medical?

Boston Scientific (BSX) gains the transcarotid artery revascularization (TCAR) platform, a minimally invasive procedure for stroke prevention and treatment of carotid artery disease.

When did Boston Scientific (BSX) complete the acquisition of Silk Road Medical?

Boston Scientific (BSX) completed the acquisition of Silk Road Medical on September 17, 2024.